Kornimate/medical-research-clean huggingface dataset:
managing adolescent obesity at local level by combining primary and secondary intervention

Conditions: Obesity

Summary: the objective of the project is to develop, implement and evaluate a prevention program for obesity among adolescents in brazil combining the primary care health system implemented in the country in recent decades with primary prevention at schools.

the study will combine primary prevention activities at the school level with secondary prevention at the household level, both focusing on behavior strategies such as mindfulness, reduction of eating rate; eating with others at a dinning table; healthy eating, increasing physical activity and reducing sedentary lifestyle habits.

Eligibility criteria:
inclusion criteria: * both prevention programs * 5th and 6th grades students * consent form signed by parents/tutors * secondary prevention program * overweight and obese children exclusion criteria: * pregnant girls

Keywords: school-based intervention sedentary behavior physical activity sugar sweetened beverages
assessment of a cosmetic product effect on the host/microorganism relationship in acneic subjects

Conditions: Acne

Summary: the aim of the study is to understand the structural and functional modifications of the host, the microorganisms, and their interactions (host/microorganism relationship) before and after the rv3278a - et0943 product application


Eligibility criteria:
inclusion criteria: 1. related to the population: - subject aged between 12 to 25 years included 2. related to diseases: * subject having acne lesions on the face, with gea (global acne evaluation) score on the face is assessed as 2 (mild) or as 3 (moderate), on a scale ranged from 0 (clear- no lesion) to 5 (very severe) * subject having at least 20 open-comedones of about 1 mm in diameter on the face and possibly extractable * subject having a predominance of non-inflammatory acne lesions exclusion criteria: 1. related to diseases: * subject having comedones only on the nose wings * subject with any other dermatological disease than acne or skin characteristics (like scar, tatoo) on the face liable to interfere with the study according to the investigator's assessment * subject with an acute or chronic disease, or history of disease liable to interfere with the study data or considered by the investigator hazardous for the subject or incompatible with the study requirements * severe form of acne (acne conglobata, acne fulminans or nodulokystic acne) or acneiform induced rashes according to the investigator's assessment * clinical signs of a hormonal dysfunction or of a hyperandrogenism * solar erythema on the face due to excessive uv exposur 2. related to the treatments/products: * any previous/concomitant treatment or product considered by the investigator liable to interfere with the study data or incompatible with the study requirements or hazardous for the subject

Keywords: comedones lipids blackheads host/microorganism relationship micro comedones
enhancing nutrition and antenatal infection treatment for maternal and child health in ethiopia

Conditions: Low Birthweight; Preterm Birth; Maternal; Malnutrition, Affecting Fetus; Sexually Transmitted Diseases; Urinary Tract Infections; Pregnancy and Infectious Disease

Summary: the enat study will test the impact of packages of antenatal interventions to enhance maternal nutrition and manage pregnancy infections on the outcomes of infant birth size, gestational length, and infant growth in the first 6 months of life. approximately 5,280 pregnant women will be enrolled into the study from 12 health centers in the amhara region of ethiopia. routine antenatal care will be strengthened in all health centers, and six health centers will be randomized to additionally provide a nutritional intervention including daily multiple-micronutrient or a fortified balanced-energy protein supplement for malnourished women. women across all 12 health centers will be individually randomized to receive one of three infection management interventions in pregnancy: 1) enhanced infection management package (screening-treatment for urinary tract infections and sexually transmitted infections, presumptive deworming); 2) presumptive azithromycin (2g at \<24 wks and a second dose at least 4 weeks later); or 3) placebo. the women and their infants will be followed until 6 months postpartum. outcomes of interest include birth size (weight, length), gestational age, maternal weight gain in pregnancy, maternal anemia, antimicrobial resistance, and infant size at 6 months.


Eligibility criteria:
inclusion criteria: * pregnant women \<=24 weeks gestation with a viable pregnancy based on a best clinical algorithm (lmp and/or symphysis fundal height) exclusion criteria: * pregnant women presenting at enrollment \>24 weeks * pregnant women presenting with non-viable fetus * women who do not intend to deliver in the study catchment area * known allergy to azithromycin or macrolide antibiotic * women who refuse to provide consent

Keywords: low birthweight preterm birth maternal nutrition small for gestational age chlamydia gonorrhea urinary tract infection presumptive antibiotics
pregnancy, childbirth intentions and outcomes under sexual pain

Conditions: Vulvodynia; Provoked Vestibulodynia

Summary: the main purpose of this study is to assess conception, pregnancy, childbirth, and pain experiences among women who have been diagnosed with vulvodynia. specifically, this study aims to examine the following among women who have been diagnosed with vulvodynia: 1) rates of pregnancy/childbirth and desire for children; 2) fear of pregnancy and childbirth; 3) potential difficulties experienced while attempting to become pregnant and during pregnancy/childbirth; 4) methods used to become pregnant and deliver; 5) methods used to manage vulvodynia symptoms during pregnancy; and 6) pain outcomes associated with pregnancy. very little research has examined pregnancy/childbirth experiences among women with vulvodynia, or the natural history of vulvodynia. as such this is a preliminary investigation that will provide descriptive information regarding many of the proposed research questions. based on the clinical experience of the investigators, it is expected that women with vulvodynia will report lower rates of pregnancy and higher levels of fear about pregnancy and childbirth in comparison to women without such pain. it is also expected that women with vulvodynia will report more difficulties becoming pregnant as compared to women without such pain, and that women with vulvodynia will report more elective nonvaginal births in comparison to vaginal births.


Eligibility criteria:
inclusion criteria: * previous diagnosis of vulvodynia from a physician (women with vulvodynia only) * assessed and/or treated at one of 3 clinics (women with vulvodynia only) * free from chronic vulvar pain and pain with sexual intercourse in their lifetime (control women only) * 19 years of age or older * fluent in english exclusion criteria: * younger than 19 years of age * lack of fluency in english

Keywords: pregnancy childbirth pain vulvodynia provoked vestibulodynia
interleukin-2 in treating patients with mycosis fungoides or sezary syndrome

Conditions: Lymphoma

Summary: rationale: interleukin-2 may stimulate a person's white blood cells to kill lymphoma cells. purpose: phase ii trial to study the effectiveness of interleukin-2 in treating patients who have mycosis fungoides or sezary syndrome.

objectives: * determine the response rate in patients with mycosis fungoides or sezary syndrome treated with interleukin-2 (il-2). * determine the toxicity of this regimen in these patients. outline: this is a multicenter study. patients receive interleukin-2 subcutaneously for 4 consecutive days a week for 6 consecutive weeks. treatment repeats every 8 weeks in the absence of disease progression or unacceptable toxicity. patients who achieve complete response or stable disease continue treatment for 2 courses past best response. patients who demonstrate a persistent partial response continue treatment in the absence of disease progression or unacceptable toxicity. patients are followed every 3 months for survival. projected accrual: a total of 15-35 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically proven mycosis fungoides or sezary syndrome * any stage * measurable disease with 1 or more indicator lesions * evaluable disease for erythrodermic patients only * at least 2 weeks since prior therapy, if documented progressive disease (pd) * at least 4 weeks since prior therapy, if best response achieved without clear evidence of pd patient characteristics: age: * 18 and over performance status: * ecog 0-2 life expectancy: * at least 3 months hematopoietic: * wbc at least 3,000/mm\^3 * absolute granulocyte count at least 1,000/mm\^3 * platelet count at least 100,000/mm\^3 hepatic: * bilirubin no greater than 2.2 mg/dl renal: * creatinine no greater than 2.0 mg/dl cardiovascular: * no new york heart association class iii or iv heart disease * no cardiac pacemaker * no clinically significant peripheral venous insufficiency other: * no other malignancy within the past 5 years except: * treated squamous cell or basal cell skin cancer * treated carcinoma in situ of the cervix * surgically treated other cancer * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * no active infection * hiv negative * no poorly controlled diabetes mellitus prior concurrent therapy: biologic therapy: * not specified chemotherapy: * see disease characteristics endocrine therapy: * no concurrent steroids radiotherapy: * see disease characteristics * no concurrent radiotherapy surgery: * not specified other: * no other concurrent proven or investigational antineoplastic therapy

Keywords: stage i cutaneous t-cell non-hodgkin lymphoma stage ii cutaneous t-cell non-hodgkin lymphoma stage iii cutaneous t-cell non-hodgkin lymphoma stage iv cutaneous t-cell non-hodgkin lymphoma recurrent cutaneous t-cell non-hodgkin lymphoma stage i mycosis fungoides/sezary syndrome stage ii mycosis fungoides/sezary syndrome stage iii mycosis fungoides/sezary syndrome stage iv mycosis fungoides/sezary syndrome recurrent mycosis fungoides/sezary syndrome
chondroitin sulfate for crohn's disease

Conditions: Crohn's Disease

Summary: pilot trial of open-label chondroitin sulfate 400 mg tid for adult patients with mild to moderate crohn's disease. primary endpoint with be evidence of bilogic effect assessed through serum and tissue cytokine analysis. secondary endpoints are evidence of clinical effect, endoscopic healing, and histologic improvment. trial duration is 8 weeks.


Eligibility criteria:
inclusion criteria: * 1. colonic or ileocolonic cd diagnosed for at least 3 months. 2. active cd, defined as a crohn's disease activity index (cdai; appendix a) \[best 1976\] of greater than 200 but less than 320 at the time entry into the study. 3. age \> 18 years. 4. patients receiving oral or topical 5-aminosalicylates must be on a stable dose for four weeks prior to enrollment. 5. patients on azathioprine, 6-mercaptopurine, or methotrexate must be on stable doses for 14 weeks prior to enrollment. 6. patients on corticosteroids must be on stable doses for 2 weeks prior to enrollment. 7. patients receiving corticosteroid enemas must be on a stable dose for 3 weeks prior to enrollment. 8. patient on biologic therapy with infliximab, adalimumab, or certolizumab must be on stable therapy for 12 weeks prior to enrollment 9. patient must sign informed consent. exclusion criteria: * 1. patients with only small bowel cd, fistulizing cd, or gastroduodenal cd without colonic involvement. 2. patients with known ulcerative colitis. 3. patients expected to require surgery within 30 days for complications of cd. 4. patients with cd and an intraabdominal abscess. 5. patients requiring continuous antibiotics; antibiotics may be taken up to the point of enrollment into the study. 6. patients with severe cardiac, pulmonary, or renal disease. 7. patients with a h/o malignancy other than resected basal cell carcinoma of the skin 8. patients who have participated in another clinical research study in the past 8 weeks. 9. patients who are pregnant.

Keywords: crohn's disease chondroitin sulfate
inhibitory control and eating disorders

Conditions: Anorexia Nervosa; Bulimia Nervosa; Binge Eating

Summary: executive functions are part of the high-level cognitive processes essential to the proper functioning of human cognition. they consist mainly of flexibility, updating and inhibition. some studies have shown a correlation between executive disorders (impaired executive function) and psychiatric disorders such as obsessive-compulsive disorder or phobias. these executive disorders are related to dysfunctions of the fronto-striatal loops. in addition, other studies have investigated the link that may exist between eating disorders such as anorexia or bulimia nervosa and executive functioning. anorexia nervosa, bulimia nervosa and binge eating disorders are eating disorders characterized by a dysfunction in food intake with restriction of food or compulsions as well as strong concerns about the body schema. concerning the executive functioning, these studies highlight a lack of cognitive flexibility for patients with anorexia nervosa and bulimia nervosa but also dysfunctions depending on the type of pathology (anorexia nervosa or bulimia nervosa). these studies also highlight the beneficial effects of cognitive remediation on people with eating disorders. however, the investigation of the inhibitory control has not yet been specifically studied. moreover, since eating disorders are structurally different, a comparison between several pathologies would be interesting to consider. the aim of this study is to determine if a dysfunction of inhibitory control can be highlighted in people with eating disorders. this study would also allow further researches about cognitive remediation suitable for the specific difficulties encountered in these diseases.


Eligibility criteria:
inclusion criteria: * woman aged 19 to 40 years old * patient with a bmi between 13 and 40 kg/m2 * outpatients of the refering center of eating disorders ('hospices civils de lyon' in lyon) suffering of an eating disorder diagnosis (anorexia nervosa, bulimia nervosa or binge eating disorder) * patient who agrees to participate to the study. exclusion criteria: * patient with psychiatric comorbidity severe (dsm v) and not stable (during the 8 weeks before inclusion) * patient with psychotropic treatment (started or modified during the 8 weeks before inclusion) * major patient protected by a measure of legal protection * patient younger than 19 years old * participation to another study at the same time
early versus late ofatumumab (kesimpta®) use in austrian rms-patients over 2 years

Conditions: Relapsing Multiple Sclerosis

Summary: this non-interventional study aims to observe the effect of early versus late ofatumumab treatment in rms patients in a real-world setting in austria over an observational period of 24 months.

this multi-center, observational study will describe the effects of ofatumumab in 2 cohorts in a routine medical care setting. cohort one will comprise patients who have started ofatumumab early during their disease (treatment naive patients or those that started ofatumumab within 3 years of first therapy initiation). cohort two will include patients who have been on other dmts (one or several) for a minimum of 3 years prior to switching to ofatumumab. patients in both cohorts will be observed for two years.

Eligibility criteria:
inclusion criteria: 1. patients with relapsing multiple sclerosis (rms) with disease activity defined by clinical assessment or mri analysis. 2. written informed consent must be obtained before participating in the study. 3. patient is willing and able to complete the assessments, as outlined in this study. 4. diagnosis of rms per mcdonald criteria (2017) occurred prior to initiation of ofatumumab. 5. patients in both cohorts must have been on treatment with ofatumumab for at least 3 months, but not longer than 12 months prior to inclusion in the study. 6. cohort 1: patients that, before initiation of ofatumumab, were either treatment naive or have started their treatment for rms with another disease modifying therapy (brace, teriflunomide or fumarates). non-naive patients in this cohort must have started the use of ofatumumab within 3 years after first dmt initiation. 7. cohort 2: patients must have been on either brace or teriflunomide or fumarates for at least three years or longer before the switch to ofatumumab has been initiated. thus, this cohort includes patients that use ofatumumab as second or later line dmt. exclusion criteria: 1. patients who have been on ofatumumab less than 3 months or more than 12 months before inclusion. 2. use of investigational drugs during the study, or between ofatumumab initiation and inclusion into the study, or within 5 half-lives of investigational drug before ofatumumab initiation, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer. 3. use of any high efficacy therapy (including fingolimod, siponimod, ponesimod, ozanimod, rituximab, ocrelizumab, natalizumab, alemtuzumab, mitoxantron or cladribine) in either cohort prior to the initiation of ofatumumab. 4. previous use of any dmts other than brace, teriflunomide or fumarates prior to the initiation of ofatumumab.

Keywords: relapsing multiple sclerosis rms ofatumumab nis
effect of music on pain and comfort levels after laparoscopic abdominal surgery

Conditions: Pain, Postoperative; Surgery

Summary: it is planned to examine the effects of local music on pain and comfort levels in patients undergoing laparoscopic abdominal surgery and to make a comparison between turkey and iran with the results obtained. the hypotheses of the study are as follows: h1-0: music has no effect on reducing pain in patients undergoing laparoscopic abdominal surgery. h1-1: music has an effect on reducing pain in patients undergoing laparoscopic abdominal surgery. h2-0: music has no effect on increasing comfort in patients undergoing laparoscopic abdominal surgery. h2-1: music has an effect on increasing comfort in patients undergoing laparoscopic abdominal surgery.

as part of the pre-test, the patient introduction form, comfort and pain scales will be applied to the experimental group patients. music will be played in the patient room 2 hours after the patients are transferred from the post-operative care unit to the clinic, which is the most appropriate time after surgery, when vital signs are stable and clinical compliance is achieved. music will be played for 20 minutes. as part of the post-test, the comfort and pain scales will be applied to the experimental group patients again. as part of the pre-test, the patient introduction form, comfort and pain scales will be applied to the control group patients. no intervention will be applied to the control group patients and the clinic's routine practices will continue. as part of the post-test, the comfort and pain scales will be applied to the control group patients again.

Eligibility criteria:
inclusion criteria: * must be over 18 years old * must not have communication problems exclusion criteria: * having any hearing or mental problems * laparoscopic surgery converted to open surgery

Keywords: music therapy pain laparoscopic surgery comfort
a cross-sectional, observational multicenter study to assess the reasons for choosing the 3-year hormonal iud and level of iuds knowledge among women aged 18 to 29 years

Conditions: Intrauterine Devices, Medicated

Summary: a cross-sectional, observational multicenter study to assess the reasons for choosing the 3-year hormonal iud and level of iuds knowledge among women aged 18 to 29 years. the study will be conducted in standard clinical practice conditions at public and private gynecology clinics and during a single study visit. approximately 1,000 women aged 18 to 29 years who have freely chosen the 3 year hormonal iud as their contraceptive method will be included in the study.


Eligibility criteria:
inclusion criteria: * women aged 18 to 29 years. * women who decided to initiate treatment with a 3-year hormonal iud for contraception after being adequately counseled and informed of all contraceptive options by their physician during a routine clinical visit, prior to the study visit (insertion visit). * women capable of reading and writing. * women who signed informed consent. exclusion criteria: * women currently participating in an interventional clinical trial. * prescription of the 3-year hormonal iud for non-contraceptive medical reasons.
prevalence of prone positioning use in ards patients

Conditions: Acute Respiratory Distress Syndrome (ARDS)

Summary: prone positioning has been shown to improve survival in patients with acute respiratory distress syndrome (ards). however, a recent large observational study found that prone positioning was used in only 7% of all ards patients, and 16% in the severe category. however, this study did not focus on the prone position per se. in present study, the investigators would like to explore the rate of use of prone positioning in ards patients and the reasons why this treatment was not applied. the present study is one-day prevalence study repeated four times over one year. the hypothesis is that the rate of use of prone position is greater than 50% in the severe ards category.


Eligibility criteria:
inclusion criteria: * 1.ards criteria (berlin definition) fulfilled the day of the study, whatever the ards stage. the onset of ards could have been established at any time between icu admission and study day but ards criteria must be still present the day of the study. the ards criteria are listed below * within 1 week of a known clinical insult or new or worsening respiratory symptoms * bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules * respiratory failure not fully explained by cardiac failure or fluid overload. need objective assessment (eg, echocardiography) to exclude hydrostatic edema if no risk factor present * 2.pao2/fio2 ≤ 300 with peep ≥ 5 cmh2o * 3.age ≥ 18 years * 4.intubated or tracheotomized and mechanically ventilated exclusion criteria: * patient non intubated the day of the study * no criteria for ards the day of the study even if these criteria were present between icu admission and day of the study

Keywords: prone position acute respiratory distress syndrome (ards) mechanical ventilation icu prevalence